Catalyst Oncology

SOUTH SAN FRANCISCO, Calif., July 13 /PRNewswire-FirstCall/ — Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq: BIIB) for the selection of a Raf kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting

Here is the original:
Press Release - Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec